The Executive Order 14017 signed by President Joseph Biden on Feb. 24, 2021 directed the Administration to launch an immediate 100-day review and strategy development process to identify and address vulnerabilities in the supply chains of four key product sectors, including pharmaceuticals, reported the U.S. Food and Drug Administration (FDA).
HHS led the development of a pharmaceutical supply chain report and its recommendations, which were published in a report by the White House on June 8, 2021. HHS and FDA will work with the private sector and Congress to implement the recommendations and develop a strategy to create a robust and resilient pharmaceutical and active pharmaceutical ingredient (API) supply chain, including facilitating adoption of novel methods for commercial production of pharmaceuticals and biologics.
Executive Order 14017 also directs HHS to develop a one-year report on supply chains for the public health and biological preparedness industrial base. Work on that report is ongoing and, like the 100-day report, is intended to complement the work conducted pursuant to Executive Order 14001 (A Sustainable Public Health Supply Chain, issued on Jan. 21, 2021). Under EO 14001, HHS is developing a Pandemic Supply Chain Resilience Strategy to design, build, and sustain a long-term capability in the United States to manufacture supplies for future pandemics. . .
Visit HPNonline.com for the full article.
